In support of this, NAMPT inhibitors enhance the anti-tumor efficacy of immune checkpoint inhibitors (i.e. antibody against PD-1; (Soncini et al., 2014; Travelli et al., 2019b). This evidence concerns the gene NAMPT and neoplasm.